A physiologically oriented mathematical model for the description of in vivo drug release and absorption by Del Cont, Renzo et al.
doi: 10.5599/admet.2.2.34 80 
ADMET & DMPK 2(2) (2014) 80-97; doi: 10.5599/admet.2.2.34 
 
Open Access : ISSN : 1848-7718  
http://www.pub.iapchem.org/ojs/index.php/admet/index   
Original scientific paper 
A physiologically-oriented mathematical model for the 
description of in vivo drug release and absorption 
Renzo Del Cont1, Michela Abrami1, Dritan Hasa2, Beatrice Perissutti2, Dario 
Voinovich2, Anna Barba3, Gaetano Lamberti4, Gabriele Grassi5, Italo Colombo1, 
Davide Manca6, Mario Grassi1* 
1
Dept. of Engineering and Architecture, Trieste University, Via Alfonso Valerio, 6/A, Trieste, I-34127 Italy  
2
Dept. of Chemical and Pharmaceutical Sciences, Trieste University, Piazzale Europa 1, Trieste, I-34127, Italy 
3
Dept. of Pharmacy, Salerno University, Via Giovanni Paolo II, 132, Fisciano (SA), I 84084 Italy 
4
Dept. of Industrial Engineering, Salerno University, Via Giovanni Paolo II, 132,  Fisciano (SA), I 84084 Italy 
5
Dept. of Life Sciences, Cattinara University Hospital, Trieste University, Strada di Fiume 447, Trieste, I-34149 Italy 
5
Dept. of Life Sciences, Cattinara University Hospital, Trieste University, Strada di Fiume 447, Trieste, I-34149 Italy 
6
 Dept. of Chemistry, Materials and Chemical Engineering "Giulio Natta" Politecnico di Milano, P.zza Leonardo Da Vinci, 
32 – Milano, I-20133 Italy. 
*Corresponding Author:  E-mail: mariog@dicamp.univ.trieste.it; Tel.: +39-040-558-3435; Fax: +39-040-569823 
Received: March 02, 2014; Revised: July 16, 2014; Published: July 18, 2014  
 
Abstract 
This paper focuses on a physiologically-oriented mathematical model aimed at studying the in vivo drug 
release, absorption, distribution, metabolism and elimination (ADME). To this purpose, the model 
accounts for drug delivery from an ensemble of non-eroding poly-disperse polymeric particles and the 
subsequent ADME processes. The model outcomes are studied with reference to three widely used drugs: 
theophylline, temazepam and nimesulide. One of the most important results of this study is the 
quantitative evaluation of the interplay between the release kinetics and the subsequent ADME processes. 
Indeed, it is usually assumed that in vivo drug release coincides with in vitro so that the effect exerted by 
the ADME processes is neglected. In addition, the proposed model may be an important tool for the design 
of delivery systems since, through proper changes, it could also account for different oral delivery systems. 
Keywords 
Mathematical modelling, in vitro release, in vivo release, pharmacokinetics. 
 
Introduction 
Quite recently, an initiative of the Pharmaceutical Research and Manufacturers of America (PhRMA) 
tried to evaluate the reliability of predictive models in terms of of drug efficacy, safety and properties 
estimation [1-3]. For this purpose, 108 clinical compounds (22 % acids, 46 % bases, 18 % zwitterions and 
14  % neutrals), supplied by 12 PhRMA member companies, have been considered. The overall goal of this 
study was to assess the predictability of human pharmacokinetics (PK) from preclinical data and to provide 
comparisons of available prediction methods from literature. In particular, Physiologically Based PK (PBPK) 
models, despite their limited application in drug discovery and development, due to their mathematical 
complexity and requirement of many experimental data, have been considered. Indeed, these models have 
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become more attractive for the prediction of human PK profiles thanks to the prediction of hepatic 
metabolic clearance and tissue distribution from in vitro and in silico data as well as the advent of 
commercially available and user-friendly software [4]. PBPK models have showed, in 69% of the cases, a 
medium to high degree of accuracy in simulating the time course of the drug plasma concentration in 
human following intravenous administration. On the contrary, the accuracy decreases to 23% in case of 
oral administration [5]. Accordingly, the authors of this study concluded that i) PBPK models can be a useful 
basis for a more rational selection of first-in-human phase dose ranges and that ii) there is a need for 
better predictions of human pharmacokinetics following oral administration. Indeed, predicting the time 
course of drug concentration in plasma/blood following oral administration presents the not negligible 
difficulty of simulating both the delivery and the absorption stages which is obviously not needed with 
intravenous administration. When efforts have been focused on taking into account one of these two 
stages, they were directed to the absorption [6], neglecting the delivery stage. As a matter of fact, both the 
PhRMA study and common commercial software consider the release stage either by assuming a fixed 
release kinetics or by providing the model with an in vitro release profile assumed to be representative of 
in vivo release [5]. In this light and considering that oral administration is by far the most common route of 
drug administration [5], we believe it is worth working on the improvement of PBPK models devoted to 
simulate PK following oral administration. In addition, we are convinced that the new challenge in the drug 
delivery field, for mathematical modelling, is to combine of mechanistic theories able to realistically 
describe the simultaneous processes of drug release and the subsequent ADME processes within the 
human body [7,8]. Indeed, this step is a fundamental prerequisite to get the final objective of building up a 
mathematical model able to predict pharmacodynamics, i.e. the clinical effect of a drug released from a 
specific delivery system [9]. Nowadays, many powerful commercial software exist for the simulation of PK 
phenomena. Among them, Simcyp, Gastroplus and PK-SIM can be cited. These commercial PBPK models 
combine a variety of functions for defining release from oral formulations with sophisticated models for 
the description of ADME processes. In particular, Simcyp is able to account for population variability of 
parameters and their covariation where known. Our mathematical model, on the contrary, tries to 
establish a deep connection between the ADME phenomena, described by a recently developed simple 
PBPK model [10], and the drug delivery step, described by a model [11,12] that proved to be reliable. In 
particular, the considered delivery system consists of an ensemble of non-eroding poly-dispersed 
polymeric particles hosting the drug inside polymeric meshes. Particulate systems, indeed, present 
remarkable advantages over the single unit devices including easier dispersion within the stomach that can 
result in an appreciable reduction of local drug concentration, and reduction of the insurgence of gastric 
irritation [13]. Moreover, particulate systems are very versatile, one more reason for their wide use. 
Mathematical Model 
PBPK model 
The mathematical representation of the human body is essentially based on the PBPK model presented 
by Di Muria and co-workers [10]. The gastrointestinal (GI) tract is described by a continuous hollow cylinder 
subdivided into three zones: the gastric lumen (GL) the small intestine lumen (SIL) and the large intestine 
lumen (LIL) (see Figure 1). The different physiological and morphological conditions (for example pH and 
internal radius) in the GI tract, account for different permeability (PGL, PSIL and PLIL, respectively), drug 






LILR , respectively) for each zone. 
The GI tract is crossed by the release environment, an aqueous volume (Vr), containing the delivery system 
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(an ensemble of drug loaded, non-eroding, poly-dispersed polymeric particles), that, due to peristaltic 
movements, flows downwards from the GL to the SIL and eventually to the LIL. For modelling purposes, it 







LILR , while the internal radius (R








Figure 1. Schematic representation of the physiologically-oriented mathematical model. The release environment 
(volume Vr), due to peristalsis, flows from the gastric environment (GL) to the small (SIL) and eventually the large (LIL) 
intestine. Once it leaves the delivery system (a non-eroding poly-disperse ensemble of polymeric particles), the drug 
reaches the release environment fluids and, then, it can permeate, by passive absorption, the GL, SIL and LIL mucosa to 
reach the gastrointestinal circulatory system (GICS). Here it reaches the liver through the portal vein (PV). Once in the 
liver, it can be eliminated by metabolic or biliary clearance (CLH) or it may reach the plasma through the hepatic vein 
(HV). Once in the plasma, it may be exchanged with the less perfused tissues, it may return to the liver through the 
hepatic artery (HA) or it can go to the CIGS following the portal vein (PV). Adapted from [10]. 
 







depending on the GI position reached by the release environment. When, on the contrary, Ri is > 0, the 
release environment assumes the shape of a hollow cylinder. In both cases, the length of the release 
environment is defined by (see Figure 1): 
    
2 2
i i




  j = GL, SIL, LIL      (1) 
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It is, thus, evident that the choice of R
i
 serves to define the (time/position dependent) contact area 
between the release environment and the GI tract Mucosa. Consequently, R
i
 can be considered a model 
fitting parameter. Lacking further physiological information, in this work, the most obvious Ri = 0 condition 
was considered. 
Due to the well-known differences in the morphology/physiology of each zone, it is supposed that the 
release environment speed (vre) can vary along the GI tract and this is indirectly considered for by setting 
three different residence (transit) times (tGL, tSIL and tLIL, respectively), one for each zone. Release 
environment velocity (vre) and position in the GI tract (Pos) are connected by the following relation: Pos = 
∫0
tvre*dt, where t is time. Thus, assuming a constant vre, the transit time (tt) of the whole GI tract is given by 
tt = Pos/vre where, now, Pos indicates the GI tract length. Alternatively, always assuming a constant vre, after 
time t, the position gained by the release environment is given by: Pos = vre*t. 
Once released, the drug can undergo elimination in the release environment (elimination constant 
RE
elk , 
dimensionally time-1) and it can cross, due to passive diffusion, the GI mucosa according to the local 
permeability that depends on the Vr position in the GI tract. Then, the drug reaches the gastrointestinal 
circulatory system (GICS), i.e. the ensemble of blood vessels around the GI tract. The compartment named 
GICS (Gastro Intestinal Circulatory System) is new to pharmacokinetic modeling, firstly introduced by [10]. 
Basically, it corresponds to the ensemble of the mesenteric artery, the portal vein and the ensemble of 
microcirculatory gastrointestinal vessels. This section of the whole circulatory system behaves differently 
from the remaining. In the case of parenteral administration, the mesenteric artery transports the drug 
towards the gastrointestinal tract. In the case of enteral administration, on the contrary, the portal vein 
transports the drug from the gastrointestinal tract towards the liver (where the drug experience the so-
called first-pass effect) to finally get the remaining part of the circulatory system (here called “plasma”) 
and the other tissues. The introduction of the GICS has allowed to effectively transform the very detailed 
pharmacokinetic model proposed by [14], (consisting in 21 compartments and 38 ordinary differential 
equations with roughly one hundred parameters), into a simple and effective model (7 compartments and 
7 ordinary differential equations, with about twenty parameters). This effort saw several researchers 
spending lot of work, with limited and ineffective results (see, for example (see, for example, [15]). The 
GICS is assumed to be a well-stirred environment characterized by its own constant volume (VGICS) and time 
dependent drug concentration (CGICS). 
The portal vein ensures the convective drug transport (blood volumetric flow QPV) from the GICS to the 
liver (volume VL). In this well-stirred environment, drug concentration (CL) varies due to hepatic clearance 
(CLH; dimensionally a volumetric flow) and convective transport by the hepatic vein and the hepatic artery. 
The hepatic vein connects the liver to the highly perfused tissues and organs (where drug concentration is 
assumed equal to plasma’s) by a volumetric blood flow QHV, while the hepatic artery brings back the drug 
from the plasma environment to the liver (volumetric blood flow QHA). Once in the plasma, the drug can 
undergo elimination (
*
elk  is the elimination constant, dimensionally a volumetric flow), convective 
transport back to the GICS according to the portal vein (again, blood volumetric flow QPV) and exchange 
with the poorly perfused tissues and organs, indicated as “tissues” in Figure 1. Drug exchange between 
plasma and tissues is ruled by the forward mass transfer coefficient 
*
PTk (from the plasma to the tissues; 
dimensionally a volumetric flow) and the reverse term 
*
TPk (from tissues to plasma; dimensionally a 




TPk  and 
*
PTk  constants are not commonly used in the PK field, their use is 
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mandatory in this case. Indeed, in order ensure that all the kinetic equations ruling drug concentration in 





TPk  and 
*
PTk  must be volumetric flows [12]. However, as this is not a common choice and it can 
generate confusion in the reader, model equations have been re-arranged so that more common drug 
elimination (kel, time
-1








TPk  and 
*




TPk  and 
*
PTk  in Eqs. (3) –(5) is represented by parameter F (see 
Eq. (8)) that expresses the ratio between the plasma (VP) and the tissues (VT) volumes. Accordingly, the 
PBPK model discussed and reported in Figure 1, is mathematically represented by the following system of 
ordinary differential equations where t is the independent variable, time: 
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where: 
 j j j2πRA L   j = GL, SIL, LIL   j , ,GL SIL SILP P P P    (7) 
 
*
el el Pk k V   
*
PT PT Pk k V   
*
TP TP Pk k V   P TF V V   (8) 
Eq. (2) allows the computing of the drug concentration in the GICS, Eq. (3) evaluates the liver drug 
concentration, Eq. (4) determines the evaluation of the plasma drug concentration, Eq. (5) calculates the 
tissues drug concentration and, finally, Eq. (6) allows calculation of the amount of drug eliminated in the 
release environment, in the liver, and in the plasma. Inspection of Eq. (2) reveals that the diffusive drug flux 
from the release environment to the GICS requires knowledge of the drug concentration in the release 
environment (Cr) that is evaluated in the following section. 
Delivery model 
Briefly, our model assumes that the drug release kinetics are essentially determined by (i) polymeric 
particles size distribution in the dry state (ii) particle swelling upon contact with the release environment 
fluid (solvent) (particle erosion is considered negligible, this being true for highly crosslinked polymeric 
networks) (iii) drug dissolution and diffusion inside particles and (iv) possible drug re-crystallisation upon 
contact with the release environment fluid. The first point is achieved by assuming that dry particle size 
distribution can be conveniently represented by a Weibull distribution function [16]:  
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where Rp and Rmin are, respectively, the generic particle radius and the minimum particle radius,  and  
are two parameters regulating the Weibull size distribution, while V0 and V arethe total volume occupied 
by the ensemble of polymeric particles and the volume occupied by particles having a radius lower than or 
equal to Rp, respectively. In order to account for particles polydispersity, the Weibull size distribution (Eq. 
(9)) is subdivided into Nc classes (from i = 1 to Nc) on the basis of the particles radius. Accordingly, particles 
of class i
th
 share the same radius Rpi. For each class, the swelling process can be evaluated by the following 
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    (11) 
where Jfi and Jri indicate the Fickian and non- fickian component of the solvent flux, respectively. Jri 
represents a delayed flux induced by the polymer/solvent viscoelastic character. D0 and Dr are, the Fickian 
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    (12) 
where Cpeq is the solvent concentration in the completely swollen polymeric network (thermodynamic 
equilibrium), eq and Deq are, respectively, the relaxation time and the solvent diffusion coefficient in 
equilibrium conditions while g and f are two model parameters evaluated in [11] by data fitting. The 
existence of two contributions in the solvent flux is motivated by the fact that the “polymer + solvent” 
system is viscoelastic, i.e. polymeric chains undergo rearrangements that develop with time (relaxation) 
upon solvent uptake. In order to account for this phenomenon, Camera-Roda and Sarti successfully 
proposed the approach expressed by Eq. (11) [17]. Eq. (10) can be solved assuming that, initially, particles 
are solvent-free, that solvent flux, for symmetry reasons, is zero in the particle centre and that solvent 
concentration at the particle surface (Cpint) is defined by: 
  
 





C C C t
t
           (13) 
The swelling part of this model is completed by assuming that the solvent-polymer mixing is ideal, i.e., 
upon swelling, particle volume can be simply computed anytime by summing polymer and solvent volume. 
Inspection of Eqs. (10) – (13) clearly reveals that solvent diffusion is assumed independent of the presence 
of drug, this being rigorously true only for low drug concentrations in the particles. 
Drug transport in the polymeric network (point iii) is modelled according to the following equations: 
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Eq. (14) represents the drug mass balance relative to the “ith” class of particles, i.e. the class of particles 
characterised by radius Rpi. This equation implies the existence of dissolved and undissolved drug inside the 
swelling polymeric network. While undissolved drug cannot move, dissolved drug mobility is controlled by 
its diffusion coefficient D that depends on the local solvent concentration Cpi according to the Peppas – 
Reinhart theory [18] (see Eq. (15)). In Eq. (15), Dds represents the drug diffusion coefficient in the pure 
solvent while i is the local polymer volume fraction and s indicates solvent density. While Ci is the 
position-dependent concentration of the dissolved drug, amdiC , 
nc
diC  and 
mc
diC  are, respectively, the position-
dependent concentrations of the undissolved drug in the amorphous, nano-crystalline and micro-
crystalline state. Indeed, in polymeric matrices, depending on the drug loading technique adopted, the 
drug can be found in amorphous, nanocrystalline and microcrystalline state [16]. As nano-crystals and 
amorphous drug are characterised by a higher solubility with respect to that of microcrystals [19], their 
presence can have a significant effect upon drug bioavailability. Whatever the state is, the drug dissolution 
rate (Eqs. (16), (18), (19)) is assumed to be proportional (K being the proportionality constant) to the 






sC  for amorphous, nano-
crystal and microcrystal drug, respectively). In principle, the model could also account for the pH 




sC . This, of course, would require the definition of a proper mathematical 
function linking solubility and pH. As the amorphous drug is often not stable and, upon dissolution, 
generally transforms into the more thermodynamically stable microcrystal condition (re-crystallisation; 
point iv)), its solubility reduces with time according to Nogami theory [20] (see Eq. (17)) where Kr is the re-
crystallisation constant and ams0C  is the maximum amorphous drug solubility. Obviously, drug re-
crystallization can also take place in the release environment and Eq. (20) serves to account for this 
phenomenon. In particular, Mc and Krb are, respectively, the amount of re-crystallized drug up to time t and 
the re-crystallization constant in the release environment. The solution of Eq. (14) is performed by 
assuming that, initially, no dissolved drug exists inside the particles (only solid or amorphous drug can be 
found in the polymeric network) and that the solid and/or amorphous drug concentration are uniform 
inside the particles (the model could easily account for more complex drug distributions). Finally, for 
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symmetry reasons, drug flux in the particle center is set to zero and the usual drug partitioning condition at 
the particle/solvent interface is considered (Kp is the drug partition coefficient). 
In order to deal with the balance between problem unknowns (CGICS, CL, Cp, CT, CPi, Ci, Cr) and equations, it is 
necessary to add a further equation for the definition of Cr. In particular, the overall drug mass balance 
made on drug is considered: 
       
pic
am nc mc 2




M V C N C R C R C R C R R R V C V C V C V C M M

               (21) 
where M0 is the administered drug dose, Nc is the number of classes into which the continuous particle size 
distribution has been subdivided into (Eq. (9)) and Npi is the number of particles belonging to the “i
th” class 
(Npi can be simply evaluated on the basis of Eq. (9)). Eq. (21) simply states that, at anytime, the summed 
drug amount in the release environment (first addendum in Eq. (21) right hand side), in the particles (sum 
of integrals in Eq. (21) right hand side), in the GICS (third addendum in Eq. (21) right hand side), in the liver 
(fourth addendum in Eq. (21) right hand side), in plasma (fifth addendum in Eq. (21) right hand side), inside 
tissues (sixth addendum in Eq. (21) right hand side) plus the drug amount recrystallized (Mc) and eliminated 
(Mel) must be equal to the administered dose M0. Interestingly, the use of Eq. (21) is allowed only if the 
other model kinetic equations (2-5) are expression of drug mass balance in the different body 
compartments considered (GICS, Liver, Plasma and Tissues). 
Due to the simultaneous presence of ordinary and partial differential equations, the solution of the model 
calls for a numerical algorithm. In particular, the ordinary differential equations have been converted into 
linear algebraic equations according to the implicit Euler method [21] while the implicit control volume 
[22] (10 particles classes, 15 radial subdivisions) has been considered for the partial differential equations 
conversion into linear and non linear algebraic equations. In order to ensure numerical solution accuracy, 
the integration time step was set to 1 s. The relaxation method [21] has been used for the iterative 
solution of our algebraic equations system. The solution of each iteration was carried out according to the 
LU decomposition approach [21]. A home-made FORTRAN code was built up for the numerical solution. 
Results and Discussion 
One of the critical factors connected to the use of PBPK models is the availability of reliable values for 
the model parameters. Of course, this is not a trivial problem [1-5] because different values for the same 
parameter can be found in the literature due, in some cases to considerable inter-subjects variability [23 – 
29]. Accordingly, in order to simplify comparison of the three different drugs considered in this paper 
(theophylline, temazepam and nimesulide), we decided to rely exclusively on the information reported in 
[10] as source of PK parameters values. 
The first drug considered, theophylline, also known as 1,3-dimethylxanthine, is a methylxanthine drug 
that finds a wide clinical use in the treatment of respiratory diseases such as asthma. Its chemical/physical 
and PK characteristics are reported in Table 1. Figure 2A shows the results of model simulations when 
assuming an orally administered dose of 100 mg dispersed in a polymeric carrier with a volume of 1 cm3. In 
particular, the continuous thick solid line refers to theophylline concentration in the plasma (Cp) in the case 
of only one spherical matrix of 6200 m radius. The initial part of the curve, characterised by zero drug 
concentration, is related to drug residence in the stomach where permeability has been set equal to zero 
(PGL = 0). Then, Cp slowly increases to a maximum followed by a subsequent drop off till the complete drug 
disappearance from the plasma. 
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Table 1. Model parameters referring to microcrystalline theophylline (release environment Vr = 250 cm
3
; polymeric 
carrier density 1.2 g/cm
3
). 












16.25 5.41 21.6 16.46 
RE
elK (1/s) Kel(1/s) KTP(1/s) KTP(1/s) 
0.0 0.0 10-6 10-6 
tGL(s) RGL(cm) iGLR (cm) PGL(cm/s) 
2880 7.5 0.0 0.0 
tSIL(s) RSIL(cm) iSILR (cm) PSIL(cm/s) 
11520.0 2.5 0.0 7.0*10-4 
tIL(s) RLIL(cm) iLILR (cm) PLIL(cm/s) 
115200.0 2.5 0.0 3.5*10-4 





0.31 0.1 10-7 10-8 
g(cm3/g) f(cm3/g) Dds(cm
2/s) Kp(-) 
5.0 12.0 7.2*10-6 1.0 
mc
sC (g/cm
3) K(1/s) Kr(1/s) Krb(1/s) 
12495 1.0 0.0 0.0 
 
The Cp increase/decrease trend corresponds to the drug absorption in the small and large intestine and 
is the result of both the simultaneous action of drug release from the matrix and the following ADME 
phenomena. The main reason for the low Cp values is the very slow drug delivery kinetics (low ratio 
between the release surface and the matrix volume, typical of big spheres) from the matrix as depicted in 
Figure 2B (see the continuous thick solid line; Cr indicates the time evolution of drug concentration in 
release environment). By keeping constant the delivery system volume (1 cm3), its splitting into all equal 
smaller particles leads to a much faster Cp increase. In particular, the thin solid line and the dashed line of 
Figure 2A represent, respectively, the Cp trend referred to particles characterised by a radius equal to 
620  m (about 103 particles) and 62 m (about 106 particles). It can be seen that, in both cases, the drug-
concentration rise is fast and Cp reaches about 5 g/cm
3 after 3.5 h in the first case (620 m) and 
6.5  g/cm3 after 2.5 h in the second case (62 m). Further reductions of particles size do not reflect in an 
appreciable variation of the Cp trend. Indeed, as shown in Figure 2B, when particles radius is around 62 m, 
the drug, totally, and very rapidly, dissolves in the release environment (stomach fluids) to get the 
maximum value compatible with the administered dose, i.e. 400 g/cm3. In this case, no control on drug 
release is exerted and the delivery system simply ensures a prompt and total release in the stomach. In 
other words, no differences occur in the Cp trend induced by this formulation or by a drug solution of the 
same dose. It is worth mentioning that the Cp trend of the 62 m particles can be approximately obtained 
by adopting an ensemble of poly-dispersed particles described by eq.(9) considering the following 
parameters:  = 1000 m,  = 2, Rmin = 0 m and Rmax = 1200 m (see the grey line in Figure 2A). The 
difference of using a poly-dispersed distribution relies on a smaller drug concentration (Cr, see grey line in 
Figure 2B) in the stomach fluids, which is advantageous in the case of stomach wall aggressive drugs. 
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Finally, it is worthwhile underlying that, based on the PK parameters set in Table 1, the time evolution of 
drug concentration in the CIGS (CGICS) and in the liver (CL) is substantially equal to that of Cp. This depends 
on the small CIGS (VGICS = 10 cm
3) and liver (VL  = 1500 cm
3) volume in comparison to the plasma (VP = 
11000 cm
3
) and tissues (VT = 24000 cm
3
) volumes and the relatively high volumetric flow connecting the 
various compartments (QHV, QPV and QHA; see Figure 1 and Table 1). 
 
Figure 2. (A) theophylline plasma concentration Cp referring to different spherical delivery systems 
characterized by the same volume (1 cm
3
) and dose (100 mg). The number close to the curves indicates 
the diameter of the sphere(s) considered while the gray line refers to a poly-disperse ensemble of 
spherical particles whose diameter spans from 0 to 1240 m. (B) theophylline concentration in the 
release environment (Cr) referring to the four delivery systems shown in (A). In the 6200 m, 620 m and 
62 m cases, the numerical solution of the model implied the subdivision of the generic particle in 500 
control volumes. In the 0 to 1240 m case, the distribution was subdivided in 10 classes and 15 control 
volumes were considered for the generic particle of each class. 
On the contrary, drug concentration (CT) in the scarcely perfused tissues and organs (tissues in Figure 1) 
monotonically increases reaching, for all formulations, values that are about two orders of magnitude 
smaller than Cp. This is essentially due to the high value of tissues volumes (VT = 24000 cm
3
). Interestingly, 
for smaller particles, Cp falls inside the theophylline therapeutic window that corresponds to 5 – 15 g/cm
3. 
The second drug considered, temazepam (TEM), a benzodiazepine derivative characterised by sedative 
and hypnotic actions, was chosen for the possibility of loading it into a polymeric carrier (such as 
crosslinked polyvinyl-pyrrolidone particles) in a completely amorphous form [11]. This, of course, can be 
highly advantageous as amorphous TEM is characterised by a much higher solubility (≈ 8649 g/cm3) with 
respect to the original macro-crystal solubility (≈ 164 g/cm3). Accordingly, we would like to theoretically 
evaluate the PK advantage of using amorphous TEM in place of its native macro-crystal condition. In 
absence of precise values of TEM PK parameters, we adopted those of a similar drug [10] while all other 
model parameters were set according to our previous study [11] (see Table 2). Figure 3A makes clear that 
amorphous TEM (thick line) shows, in PK terms, a better performance with respect to crystalline TEM (thin 
line). Indeed, not only it yields to a higher maximum CP (0.16 g/cm
3 amorphous TEM, 0.14 g/cm3, 
crystalline TEM) but, also, maximum CP occurs after about 2 h instead of about 3.5 h (crystalline TEM). This 
simulation was performed assuming that amorphous TEM re-crystallisation did not occur inside the 
stomach although we have evidence of the contrary in water [11]. Actually, as re-crystallisation kinetics can 
strongly depend also on the physical/chemical properties of the dissolving fluids (stomach fluids differ a lot 
from simple water), lacking precise information about TEM re-crystallisation in the stomach fluids, induced 
us to assume that re-crystallisation did not occur. In so doing, we estimated the maximum possible effect 
of amorphous TEM over the native crystalline TEM. Figure 3B shows that, in the amorphous case, drug 
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concentration (Cr) rapidly reaches the maximum admissible concentration (400 g/cm
3
) compatible with 
the administered dose (100 mg). This, obviously, takes place in the stomach (t < 0.8 h) while, once in the 
SIL and, eventually, in the LIL, Cr decreases up to disappearing. In the crystalline case, on the contrary, Cr 
increase is smaller and the maximum value is well below that reached in the amorphous case. 
Table 2. Model parameters referring to temazepam (release environment Vr = 250 cm
3
















16.25 5.41 21.6 16.46 
RE
elK (1/s) Kel(1/s) KTP(1/s) KTP(1/s) 
0.0 0.0 6.4*10-5 10-6 
tGL(s) RGL(cm) iGLR (cm) PGL(cm/s) 
2880 7.5 0.0 0.0 
tSIL(s) RSIL(cm) iSILR (cm) PSIL(cm/s) 
11520.0 2.5 0.0 6.0*10-4 
tIL(s) RLIL(cm) iLILR (cm) PLIL(cm/s) 
115200.0 2.5 0.0 3.0*10-4 





0.31 0.35 10-7 10-10 
g(cm3/g) f(cm3/g) Dds(cm
2/s) Kp(-) 
52.0 12.0 7.2*10-6 1.0 
mc
sC (g/cm
3) K(1/s) Kr(1/s) Krb(1/s) 







At the same time, Cr reduction in the SIL and in the LIL is slower thus ensuring higher Cp from 4 hours 
onwards. In the case of a system characterised by 50 % amorphous TEM and 50 % crystalline TEM, both the 
Cp and the Cr trends are, more or less, in between those competing to the completely amorphous and the 
totally crystalline TEM as depicted by the grey lines in Figure 3A and 3B. Finally, it is interesting to notice 
that Cr fastest variations occur when the delivery system leaves the stomach (0.8 h) and the LIL (3.2 h) 
(Figure 3B) and this is determined by the GI tract permeability variation. 
The last drug considered is nimesulide, a typical non-steroidal anti-inflammatory drug that has been 
largely employed in clinical practice [30]. Like TEM, it is scarcely soluble in aqueous media but its solubility 
is pH dependent as it is a weak acid (pKa = 6.46 [31]). Thus, water solubility at 37 °C is around 10 g/cm3 
for pH < pKa, while solubility increases to about 100 g/cm3 with higher pH [32]. Obviously, nimesulide 
solubility can be improved by using it in its amorphous/nano-crystalline state [19]. In addition, the first-
pass liver effect for nimesulide is negligible [30]. 
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Figure 3. (A) temazepam plasma concentration Cp referring to amorphous (thick black line) and 
crystalline (thin black line) drug. The gray line refers to a system containing 50% amorphous and 50% 
crystalline temazepam. Delivery systems volume is equal to 1 cm
3
 and dose is equal to 100 mg. (B) 
temazepam concentration in the release environment (Cr) referring to the three delivery systems shown 
in (A). The numerical solution of the model implied the subdivision of the particles size distribution in 10 
classes and 15 control volumes were considered for the generic particle of each class. 
While some PK parameters [10,16,30] and all the delivery parameters [11,19] can be deduced from 
literature, we could not find reliable estimation of its solubility in the gastric environment and its 
permeability through the GL, SIL and LIL mucosa. Thus, our model was fitted (four fitting parameters) to 
experimental data referring to the oral administration (three humans) of a commercial prompt action 
formulation containing nimesulide (100 mg) [33]. Fitting procedure was performed assuming that 
nimesulide is embodied in macro-crystal form inside a polymeric carrier showing the physical-chemical 
characteristics reported in Table 3 (they are similar to those competing to polyvinyl-pyrrolidone particles 
considered in the TEM case). In addition, 
i
GLR  was set to 7.3 cm so that the stomach absorption surface 
equals the one normally found in humans (around 1 m
2
 [16]). Figure 4A reports the very good agreement 
between model best fitting (solid thin line) and experimental data (open circles) being fitting parameters 
mc
sC  = 39 g/cm
3
, PGL = 6*10
-4
 cm/s, PSIL = 8.3*10
-5
 cm/s and PLIL = 7*10
-5
 cm/s. These permeability values 
indicate that nimesulide is rapidly absorbed by the gastric mucosa while its absorption in the SIL and LIL is 
slower due to the reduction of permeability (one order of magnitude). These results seem reasonable. 
Indeed, the acid environment of the stomach is particularly favorable for the absorption of nimesulide that, 
at low pH (< 3; nimesulide is a weak acid with pKa = 6.46) is completely un-dissociated (un-ionized) and this 
condition favors its passive absorption by the lipid mucosal membrane. On the contrary, for higher pH, 
such as that found in the small intestine, nimesulide is partially or totally dissociated (ionized) and this 
condition hinders nimesulide crossing of the lipophilic mucosal membrane. Accordingly, chemical and 
physical properties should be responsible for the nimesulide different permeability through the GI tract 
rather than other reasons such as the effect of intestinal wall transporters. These chemico-phyiscal 
considerations have been supported by studies about the regional absorption of nimesulide [34, 35], led on 
healthy volunteers (gamma scintigraphy). These studies proved that stomach and proximal small bowel 
account for 40 % of nimesulide absorption. 
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Table 3. Model parameters referring to nimesulide (release environment Vr = 250 cm
3
















16.25 5.41 21.6 0.49 
RE
elK (1/s) Kel(1/s) KTP(1/s) KTP(1/s) 
0.0 0.0 10-6 10-6 
tGL(s) RGL(cm) iGLR (cm) PGL(cm/s) 
2880 7.5 7.3 6.0*10-4 
tSIL(s) RSIL(cm) iSILR (cm) PSIL(cm/s) 
11520.0 2.5 0.0 8.3*10-5 
tIL(s) RLIL(cm) iLILR (cm) PLIL(cm/s) 
115200.0 2.5 0.0 7.0*10-5 





0.31 0.35 10-7 10-8 
g(cm3/g) f(cm3/g) Dds(cm
2/s) Kp(-) 
5.0 12.0 10-6 1.0 
am
sC  (g/cm
3) K(1/s) Kr(1/s) Krb(1/s) 
4108 2.0 0.06 0.0 
mc
sC (g/cm
3) pH > 6.4 mcsC  (g/cm
3) pH < 6.4 
100 39 
 
As in the TEM case, nimesulide absorption can be improved by considering its amorphous form. Figure 
4A shows the predicted plasma concentration Cp (thick line) in the case of amorphous nimesulide 
assuming, as done in the TEM case, that no re-crystallisation takes place (Krb = 0). Thus, this prediction 
should represent the maximum expected effect of amorphous nimesulide. It can be seen that the 
maximum concentration is considerably increased and, up to about 5 hours, drug concentration (thick line) 
is higher than that of the macro-crystal case (thin line). This behavior in the plasma is explained by 
Figure 4B where drug concentration in the release environment (Cr) is reported for the amorphous drug 
(thick line) and the macro-crystalline drug (thin line). Basically, in the amorphous case, nimesulide is rapidly 
released in the first 6 minutes and its concentration becomes about one order of magnitude higher than 
that corresponding to the macro-crystal case. This means that its onset of action is considerably increased, 
a desirable feature for a rapid pain relief. Also in this case, the time evolutions of drug concentration in the 
CIGS (CGICS) and in the liver (CL) are substantially equal to the Cp one and the reasons are the same as the 
theophylline case’s. 
Again, drug concentration (CT) in the scarcely perfused tissues and organs monotonically increases 
reaching, for all formulations, values that are about two order of magnitude smaller than Cp. The abrupt 
increase of Cr occurring after 1 h, in both the crystalline and amorphous case, is simply due to the reduced 
value of drug permeability in the LIL. Indeed, permeability reduction implies the decrease of the drug flux 
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Figure 4. (A) nimesulide plasma concentration Cp referring to amorphous (thick line) and crystalline (thin 
line) drug. Open circles indicate experimental data (average of three subjects; vertical bars indicate 
standard error) on which the model was fit to (thin line). Delivery systems volume is equal to 1 cm
3
 and 
dose is equal to 100 mg. (B) nimesulide concentration in the release environment (Cr) referring to the 
two delivery systems shown in (A). The numerical solution of the model implied the subdivision of the 
particles distribution in 10 classes and 15 control volumes were considered for the generic particle of 
each class. 
Conclusions 
Although the problem of a reliable prediction of drug concentration in plasma following oral 
administration remains a challenging task, a considerable development in this direction is represented by 
mathematical models able to simultaneously account for the in vivo drug release and the subsequent 
absorption, distribution, metabolism and elimination processes (ADME). In this frame, we built up a 
reasonable mathematical model resulting from merging a physiologically oriented PK model and a delivery 
model. Wherever the final aim is to get a reliable in vivo simulation, at present, we set up a theoretical tool 
that enables to rationally compare either different formulations of the same drug or the same formulation 
for different drugs. Indeed, our model allows the evaluation of the effect of different doses, different mean 
particles size and particle sizes distribution, and the drug solid states, i.e. amorphous, nano-crystalline and 
macro-crystalline drug. According to us, our model demonstrates that in vivo release kinetics can be 
different from the in vitro one due to the effect of living tissues. In other words, while the mutual effect 
between drug release and ADME processes is well known, this paper represents one of the first attempts 
of clearly evaluating and quantifying it. In conclusion, our model represents a rational tool for the designing 
of modern delivery systems and it should constitute an important step on the way to reliable simulation of 
plasma drug concentration following oral administration.  
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List of Symbols 
ADME Adsorption, Distribution, Metabolism, Elimination 
Aj contact area between the release environment and the j = GL, SIL and LIL GI tracts 
am
diC  concentration of the undissolved amorphous drug 
nc
diC  concentration of the undissolved nano-crystalline drug 
mc
diC  concentration of the undissolved micro-crystalline drug 
CGICS drug concentration in the Gastro Intestinal Circulatory System 
Ci drug concentration in the i
th
 polymeric particle 
CL drug concentration in the liver 
CLH hepatic clearance 
CP drug concentration in the plasma 
CPi solvent concentration in the polymeric particle of class i
th 
CPint solvent concentration at the polymeric particle/solvent interface 
CPeq equilibrium solvent concentration in the polymeric particles 
Cr drug concentration in the release environment 
CsGL drug solubility in the gastric lumen 
CsSIL drug solubility in the small intestine lumen 
CsLIL drug solubility in the large intestine lumen 
am
sC  time dependent amorphous drug solubility in the solvent 
am
s0C  maximum value of the amorphous drug solubility in the solvent 
nc
sC  nano-crystalline drug solubility in the solvent 
mc
sC  macro-crystalline drug solubility in the solvent 
CT drug concentration in tissues 
D drug diffusion coefficient in the swelling polymeric network 
D0 Fickian solvent diffusion coefficient 
Dds drug diffusion coefficient in the pure solvent 
Deq equilibrium diffusion coefficient of solvent 
Dr non-Fickian solvent diffusion coefficient  
F ratio between plasma and tissues volumes 
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f parameter appearing in eq.(12) 
g parameter appearing in eq.(12) 
HA epatic artery 
HV epatic vein 
GI Gastro-Intestinal 
GICS Gastro Intestinal Circulatory System 
GL gastric lumen 
K drug dissolution constant 
*
elk  drug elimination constant in the plasma (volumetric flow) 
kel drug elimination constant in the plasma (time
-1) 
*
PTk  mass transfer coefficient between plasma and tissues (volumetric flow) 




TPk  mass transfer coefficient between tissues and plasma (volumetric flow) 




elk  drug elimination constant in the GI tract 
Kp partition coefficient (particle/solvent) 
Kr drug re-crystallisation constant in the polymeric network 
Krb drug re-crystallisation constant in the release environment 
Ji solvent flux (i
th
 polymeric particle class) 
Jfi Fickian component of Ji 
Jri non-Fickian component of Ji 
Lj release environment length in j = GL, SIL, LIL 
LIL large intestine lumen 
Mc amount of the drug re-crystallised in the release environment 
Mel amount of drug eliminated in the Gi tract, in the plasma and in the liver 
M0 drug dose 
Nc number of classes characterised by polymeric particles having the same radius 
Npi number of particles belonging to i
th class 
PBPK Physiologically Based PharmacoKinetic 
PK Pharmacokinetic 
PGL drug permeability in the gastric lumen 
PLIL drug permeability in the large intestine lumen 
Pos release environment position in the GI tract 
PSIL drug permeability in the small intestine lumen 
PV portal vein 
QHV blood volumetric flow of the hepatic vein 
QHA blood volumetric flow of the hepatic artery 
QPV blood volumetric flow of the portal vein 
Rij internal radius of the release environment in the j = GL, SIL and LIL 
Ri radial coordinate (i
th particle class) 
i
GLR  internal radius of the gastric lumen 
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i
LILR  internal radius of the large intestine lumen 
i
SILR  internal radius of the small intestine lumen 
Rp polymeric particle radius 
Rpi radius of the i
th
 polymeric particle class 
Rmax maximum value of Rp 
Rmin minimum value of Rp 
t time 
TEM temazepam 
tGL  gastric lumen transit time 
tLIL  large intestine lumen transit time 
tSIL  small intestine lumen transit time 
tt  GI tract transit time 
SIL small intestine lumen 
V volume of the polymeric particles with radius lower than or equal to Rp 
V0 volume of all the polymeric particles 
VGICS volume of the Gastro Intestinal Circulatory System 
VL liver volume 
VP plasma volume 
vre release environment speed 
Vr release environment volume 
VT tissues volume 
 
Greek letters 
s solvent density 
 Weibull model parameter (eq.(9)) 
 Weibull model parameter (eq.(9)) 
 relaxation time of the polymer-solvent system (eq.(11)) 
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